Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Astrid Gast
  • CEVEC has struck a licensing deal with NewLink Genetics: its tailor-made recombinant glycoproteins and gene therapy vectors will be leveraged in new Zika Virus vaccines
 Elena Kotova
  • Ergomed’s partner, Ferrer, has announced positive Phase II results results for Lorediplon for treating insomnia
  • Sanofi and Regeneron’s Praluent will live to see another day as the companies won a stay from the US court of appeals
  • Lundbeck is calling it quits on its Alzheimer’s candidate after a late-stage failure
  • Targovax has some good news from Phase I/II for pancreatic cancer
 tache
  • Ablynx submitted an MAA for a Phase II nanobody treating a rare blood disease
  • Copenhagen is jockeying to host the EMA
Previous post

Biggest traffic ever on Labiotech.eu: 70 000 Visitors in January!

Next post

Germany gains Strength in Allergy Immunotherapeutics